Price
No data yet.
Social Signal Score
Analyst Ratings
22 analystsRevenue
$151.75M+731.21%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Marc Stapley
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 755
- Beta
- 1.96
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 8.94
Financials
Revenue
$151.75M+731.2%Net Income
$31.50MEBITDA
$27.10MFree Cash Flow
$37.92MEPS (diluted)
$0.38Shares Outstanding (diluted)
82.78M+161.1%Operating Expenses
$90.11MCash & Debt
$370.53MReturn of Capital
$0.00Revenue by Segment (annual)
$517.14MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $517.14M | $66.35M | $0.84 |
| 2024 | $445.76M | $24.14M | $0.32 |
| 2023 | $361.05M | $-74.40M | $-1.02 |
| 2022 | $296.54M | $-36.56M | $-0.51 |
| 2021 | $219.51M | $-75.56M | $-1.11 |
| 2020 | $117.48M | $-34.91M | $-0.66 |
| 2019 | $120.37M | $-12.60M | $-0.27 |
| 2018 | $92.01M | $-23.00M | $-0.62 |
| 2017 | $71.95M | $-31.00M | $-0.91 |
| 2016 | $65.08M | $-31.36M | $-1.09 |
| 2015 | $49.50M | $-33.70M | $-1.30 |
| 2014 | $38.19M | $-29.37M | $-1.36 |
| 2013 | $21.88M | $-25.58M | $-6.15 |
| 2012 | $11.63M | $-18.65M | $-1.31 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $1.24
- Implied price
- $62.03
- Return from $24.32
- 20.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $30.84 — today's price is already 21.1% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 34 | 42 | 50 | 58 | 66 |
|---|---|---|---|---|---|
| -2.0% | 1.3% | 5.7% | 9.4% | 12.7% | 15.7% |
| 3.0% | 6.5% | 11.1% | 15.0% | 18.5% | 21.6% |
| 8.0% | 11.6% | 16.5% | 20.6% | 24.2% | 27.5% |
| 13.0% | 16.8% | 21.9% | 26.2% | 30.0% | 33.4% |
| 18.0% | 22.0% | 27.2% | 31.8% | 35.7% | 39.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
0-100.00%Social Signal Score
Mentions (25)
- Newsbusinesswire.com·13d ago·Negative
VCYT Investors Have Opportunity to Join Veracyte, Inc. Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $VCYT--VCYT Investors Have Opportunity to Join Veracyte, Inc. Fraud Investigation with SBS Law.
View source ↗ - Newszacks.com·16d ago·Positive
Veracyte Q3 Earnings Call Highlights Slower Growth and Added Investment VCYT beats Q3 earnings estimates but trims its 2026 revenue outlook as Decipher growth slows and investments in breast and bladder cancer testing rise.
View source ↗ - Newsseekingalpha.com·16d ago·Positive
Veracyte, Inc. (VCYT) Q3 2026 Earnings Call Transcript Veracyte, Inc. ( VCYT ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Kelly Gura - Director of Investor Relations Marc Stapley - CEO & Director Rebecca Chambers - Executive VP & CFO John Leite - Global Chief Commercial Officer Conference Call Participants Puneet Souda - Leerink Partners LLC, Research Division Douglas Schenkel Lauren Timmins - Jefferies LLC, Research Division Mason Carrico - Stephens Inc., Research D…
View source ↗ - News (Marketaux)thestockmarketwatch.com·17d ago·Positive
Tech Sell-Off and Rising Volatility Pressure Markets as Earnings Season Hits High Gear Other notable movers include Veracyt[+326 characters]
View source ↗ - News (RSS)zerohedge·17d ago·Neutral
…ries company’s first-quarter results topped Wall Street expectations, and management boosted its annual guidance, as well as its capital returns projection.Veracyte (VCYT) tumbles 31% after the diagnostics company’s full-year revenue forecast fell short of Wall Street estimates.Wendy’s (WEN) slips 1% after the company rejected the takeover proposal from a Trian Partners-led group.Zillow (Z) falls 14% after the digital real estate company reported adjusted earnings per share and revenue for the t…
View source ↗ - Newsmarketbeat.com·17d ago·Negative
What Veracyte (VCYT) Said on Its Q3 Earnings Call Veracyte NASDAQ: VCYT reported 15% revenue growth for the third quarter of 2026, but lowered its near-term expectations for its Decipher Prostate test after volume came in below management's forecast. The company also outlined a preliminary 2027 outlook for mid-single-digit revenue growth as it invests in its commercial teams and expands its cancer testing portfolio.
View source ↗ - Newsglobenewswire.com·24d ago·Neutral
Veracyte to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it will be participating in the following investor conferences: UBS Global Healthcare Conference – Palm Beach Gardens, FLFireside chat on Tuesday, November 10 at 4:15 p.m.
View source ↗ - Newszacks.com·25d ago·Neutral
Veracyte (VCYT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Veracyte (VCYT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
View source ↗ - Newsglobenewswire.com·30d ago·Negative
Phase III Trial Shows Veracyte's Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer STAMPEDE study analysis providing new predictive evidence in clinically very high-risk, nonmetastatic disease to be presented at ESMO STAMPEDE study analysis providing new predictive evidence in clinically very high-risk, nonmetastatic disease to be presented at ESMO
View source ↗ - Newszacks.com·32d ago·Neutral
Will Veracyte (VCYT) Beat Estimates Again in Its Next Earnings Report? Veracyte (VCYT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
Six Studies to Highlight Veracyte's Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026 SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that six studies involving its genomic tests will be presented at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain.
View source ↗ - Newsglobenewswire.com·37d ago·Neutral
Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test Milestone supports broader U.S. adoption of Prosigna and expands access for eligible patients with early-stage breast cancer Milestone supports broader U.S. adoption of Prosigna and expands access for eligible patients with early-stage breast cancer
View source ↗ - Newsglobenewswire.com·39d ago·Neutral
Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026 SOUTH SAN FRANCISCO, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter 2026 after the close of market on Wednesday, November 4, 2026.
View source ↗ - Newsglobenewswire.com·54d ago·Negative
Phase III Trial Demonstrates Veracyte's Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation SOUTH SAN FRANCISCO, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced that new findings from a retrospective ancillary analysis of the randomized phase III NRG/RTOG 0815 trial will be presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting.
View source ↗ - Newsglobenewswire.com·58d ago·Negative
Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026 Six oral presentations and two posters will highlight Decipher's prognostic and predictive value in identifying patients' risk of progression and likelihood of benefiting from treatment intensification Six oral presentations and two posters will highlight Decipher's prognostic and predictive value in identifying patients' risk of progression and likelihood of benefiting from treatment intensification
View source ↗ - Newszacks.com·58d ago·Positive
Veracyte (VCYT) Surges 10.8%: Is This an Indication of Further Gains? Veracyte (VCYT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
View source ↗ - Newsseekingalpha.com·68d ago·Positive
Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·69d ago·Neutral
Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey
View source ↗ - Newsgurufocus.com·74d ago·Neutral
Veracyte Inc (VCYT) Shares Surge 3.3% -- What GF Score of 81 Tells Investors On September 09, 2026, Veracyte Inc (VCYT) shares rose 3.3% to $43.85, reflecting a slight uptick amid a challenging price performance over the past month, whic
View source ↗ - Newsglobenewswire.com·82d ago·Neutral
Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 7:00 a.m. Eastern Time.
View source ↗ - Newszacks.com·88d ago·Neutral
Is it Worth Adding Veracyte Stock to Your Portfolio Now? VCYT's Afirma and Decipher sales momentum supports growth, while competition, macro pressures and rising investments remain key concerns.
View source ↗ - Newszacks.com·89d ago·Neutral
VCYT Drops 25.3% in the Past Month. Is the Sell-Off an Opportunity? Veracyte's 25.3% sell-off improves the entry price as strong core test demand and earnings growth face valuation, reimbursement and launch risks.
View source ↗ - Newszacks.com·97d ago·Neutral
Down 30.2% in 4 Weeks, Here's Why Veracyte (VCYT) Looks Ripe for a Turnaround Veracyte (VCYT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
View source ↗ - Newsseekingalpha.com·104d ago·Positive
Veracyte: Diagnostics With Favorable Economics Veracyte's core tests are Decipher and Afirma. Both of these tests are producing double-digit growth with improving margins. I think that bodes well for VCYT's potential as a long-term cash flow machine. Moreover, VCYT's Prosigna and TrueMRD add more long-term upside, which management hasn't yet included in its recent 2026 testing-revenue guidance.
View source ↗ - Newsseekingalpha.com·104d ago·Neutral
Veracyte: Core Growth Funds Prosigna And TrueMRD Veracyte (VCYT) is evolving into a self-funded cancer diagnostic platform, leveraging clinical evidence, specialist relationships, and reimbursement infrastructure. Q2 2026 results showed 15% revenue growth, 23% adjusted EBITDA growth, and 29.2% EBITDA margin, with robust cash generation and no funded debt. Prosigna and TrueMRD launches offer significant upside, as 2026 guidance excludes their contributions, while Decipher and Afirma drive core gr
View source ↗
Earnings
Wed, Feb 24(in 3 months)
Consensus estimate $0.40 per share
Typical surprise +41.9% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$0.51 vs $0.41beat
- Thu, Jul 30$0.54 vs $0.41beat
- Tue, May 5$0.52 vs $0.34beat
- Wed, Feb 25$0.53 vs $0.41beat
- Tue, Nov 4$0.51 vs $0.32beat
- Wed, Aug 6$0.44 vs $0.31beat
Estimates and results for VCYT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by VCYT officers and directors.
- Bought
- —
- Sold
- $17.5m
0 trades
38 trades
- Holstein Jenssold
- Eastham Karinsold
- Bhanji Munasold
- Holstein Jenssold
- Leite Johnsold
- Holstein Jenssold
- Febbo Phillip G.sold
- Febbo Phillip G.sold
62 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Cisneroshouse · CA31 · disclosed Apr 8, 2026 (36d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Mar 10, 2026 (20d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Dec 15, 2025 (33d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jul 11, 2025 (25d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Nov 11, 2023 (26d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Oct 15, 2023 (30d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed May 19, 2023 (39d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jan 11, 2021 (19d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jan 11, 2021 (32d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jan 7, 2021 (30d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Nov 5, 2020 (7d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Feb 18, 2020 (32d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jan 10, 2020 (17d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jan 10, 2020 (29d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jan 6, 2020 (31d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
